Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Myeloma comparative sequencing points to Plexxikon now, personal therapies later

This article was originally published in Scrip

Executive Summary

A multi-patient whole genome analysis study in multiple myeloma recently published in Nature which is "just the beginning" of a deeper understanding of the disease, according to its authors, has already identified an entirely new potential molecular target and given a clear signal that a drug currently showing promise in melanoma might also be effective in a significant minority of multiple myeloma patients. The publication represents the first time that multiple cancer of the same time have been comparable at the whole genome level.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts